Siga Technologies Inc is a biotechnology company focused on developing solutions for public health threats, particularly through its innovative antiviral therapeutics
The company's primary emphasis is on the advancement of treatments for viral infections, with a notable concentration on smallpox and other serious infectious diseases. By leveraging its proprietary technologies, Siga aims to address unmet medical needs and improve health outcomes, especially in the face of potential bioterrorism threats or emerging viral outbreaks. Through collaborations with government entities and investment in research, the company endeavors to enhance global health security and preparedness through effective medical interventions.
NEW YORK, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against SIGA Technologies, Inc. (“SIGA” or the “Company”) (NASDAQSIGA) on behalf of SIGA stockholders. Our investigation concerns whether SIGA has violated the federal securities laws and/or engaged in other unlawful business practices.
The law firm of Kirby McInerney LLP is investigating potential claims against SIGA Technologies, Inc. (“SIGA” or the “Company”) (NASDAQSIGA). The investigation concerns whether SIGA and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of SIGA Technologies, Inc. (“SIGA” or the “Company”) (NASDAQSIGA) investors concerning the Company’s possible violations of the federal securities laws.
Law Offices of Howard G. Smith announces an investigation on behalf of SIGA Technologies, Inc. (“SIGA” or the “Company”) (NASDAQSIGA) investors concerning the Company’s possible violations of federal securities laws.
The Law Offices of Frank R. Cruz announces an investigation of SIGA Technologies, Inc. (“SIGA” or the “Company”) (NASDAQSIGA) on behalf of investors concerning the Company’s possible violations of federal securities laws.
SIGA Technologies secures a $9 million DoD contract for TPOXX, boosting total outstanding orders to $154 million. Recent BARDA and DoD wins reinforce growth despite challenges in a key mpox trial.
GeoVax Labs has seen its shares rise enormously over the past few days after an announcement from the World Health Organization relevant to one of its drugs.
Several healthcare stocks associated with mpox are seeing increased attention Thursday after the World Health Organization declared a public health emergency in response to an mpox outbreak in Africa.
Russell 2000 ETF (ARCA: IWM) up 2.7%, its strongest session in a month, driven by positive economic data & increased consumer spending, boosting confidence in US economy.
"NIH's NIAID reveals results from the PALM 007 trial of SIGA Technologies' Tpoxx for monkeypox (mpox) treatment. The study missed its primary endpoint but showed potential benefits in early and severe cases. Learn more about the safety profile and market impact on SIGA stock.
